Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy.
Authors
Munir, TRawstron, A
Brock, K
Vicente, S
Yates, F
Bishop, R
Fegan, C
Macdonald, D
Mccaig, A
Schuh, A
Pettitt, A
Gribben, J
Devereux, S
Bloor, Adrian
Fox, C
Forconi, F
Hillmen, P
Affiliation
Haematology,H.M.D.S., St James’s University Hospital,LeedsIssue Date
2018